ArticleInfection and immunity2022
Chlamydia Deficient in Plasmid-Encoded Glycoprotein 3 (pGP3) as an Attenuated Live Oral Vaccine.
Article in Infection and immunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Inhibition of a live-attenuated chlamydia oral vaccine in the large intestine is dependent on CD11c-expressing cells that produce IL-23.Scientific reports · 2026Article
- Identification of collaborative cross mouse strains susceptible to chlamydial induction of hydrosalpinx.Infection and immunity · 2026Article
- IFNγ-producing iNKTs restrict a live-attenuated chlamydia oral vaccine in the large intestine.Frontiers in immunology · 2026Article
- Pathogenic and Protective Roles of Neutrophils inPathogens (Basel, Switzerland) · 2025Review
- Article
- Advances in vaccine development for Chlamydia trachomatis.Pathogens and disease · 2024Review
- Regulation of chlamydial spreading from the small intestine to the large intestine by IL-22-producing CD4Infection and immunity · 2024Article
- IL-23 receptor signaling licenses group 3-like innate lymphoid cells to restrict a live-attenuated oral Chlamydia vaccine in the gut.Infection and immunity · 2023Article
- Preclinical screen for protection efficacy of chlamydial antigens that are immunogenic in humans.Infection and immunity · 2023Article
- Induction of Transmucosal Protection by Oral Vaccination with an Attenuated Chlamydia.Infection and immunity · 2023Article
- Potential Therapeutic Candidates againstInternational journal of environmental research and public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Despite the extensive efforts, there is still a lack of a licensed vaccine against Chlamydia trachomatis in humans. The mouse genital tract infection with Chlamydia muridarum has been used to both investigate chlamydial pathogenic mechanisms and evaluate vaccine candidates due to the C. muridarum
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.